BG64051B1 - Нова сол - Google Patents

Нова сол Download PDF

Info

Publication number
BG64051B1
BG64051B1 BG103949A BG10394999A BG64051B1 BG 64051 B1 BG64051 B1 BG 64051B1 BG 103949 A BG103949 A BG 103949A BG 10394999 A BG10394999 A BG 10394999A BG 64051 B1 BG64051 B1 BG 64051B1
Authority
BG
Bulgaria
Prior art keywords
salt
fluoro
benzopyran
dihydro
manufacture
Prior art date
Application number
BG103949A
Other languages
Bulgarian (bg)
English (en)
Other versions
BG103949A (en
Inventor
Hakan Nyqvist
Daniel Sohn
Original Assignee
Astra Aktiebolag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Aktiebolag filed Critical Astra Aktiebolag
Publication of BG103949A publication Critical patent/BG103949A/xx
Publication of BG64051B1 publication Critical patent/BG64051B1/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
BG103949A 1997-05-30 1999-12-03 Нова сол BG64051B1 (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9702066A SE510305C2 (sv) 1997-05-30 1997-05-30 Nytt salt
PCT/SE1998/000907 WO1998054166A1 (en) 1997-05-30 1998-05-15 A new salt

Publications (2)

Publication Number Publication Date
BG103949A BG103949A (en) 2000-07-31
BG64051B1 true BG64051B1 (bg) 2003-11-28

Family

ID=20407187

Family Applications (1)

Application Number Title Priority Date Filing Date
BG103949A BG64051B1 (bg) 1997-05-30 1999-12-03 Нова сол

Country Status (34)

Country Link
US (2) US6858645B2 (ko)
EP (1) EP0984952B1 (ko)
JP (1) JP3554338B2 (ko)
KR (1) KR20010013127A (ko)
CN (1) CN1198814C (ko)
AR (1) AR012751A1 (ko)
AT (1) ATE228121T1 (ko)
AU (1) AU729301B2 (ko)
BG (1) BG64051B1 (ko)
BR (1) BR9809519A (ko)
CA (1) CA2291732C (ko)
DE (1) DE69809547T2 (ko)
DK (1) DK0984952T3 (ko)
EE (1) EE03874B1 (ko)
ES (1) ES2187030T3 (ko)
HK (1) HK1025575A1 (ko)
HU (1) HUP0001878A3 (ko)
ID (1) ID23794A (ko)
IL (1) IL133234A (ko)
IS (1) IS1943B (ko)
MY (1) MY117960A (ko)
NO (1) NO995853L (ko)
NZ (1) NZ501075A (ko)
PL (1) PL337181A1 (ko)
PT (1) PT984952E (ko)
RU (1) RU2193560C2 (ko)
SE (1) SE510305C2 (ko)
SK (1) SK282755B6 (ko)
TR (1) TR199902926T2 (ko)
TW (1) TW510899B (ko)
UA (1) UA53720C2 (ko)
WO (1) WO1998054166A1 (ko)
YU (1) YU62499A (ko)
ZA (1) ZA984486B (ko)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102888D0 (sv) * 2001-08-29 2001-08-29 Astrazeneca Ab New formulation
SE0102887D0 (sv) * 2001-08-29 2001-08-29 Astrazeneca Ab New formulation
SE0102886D0 (sv) * 2001-08-29 2001-08-29 Astrazeneca Ab New formulation
SE0301796D0 (sv) * 2003-06-19 2003-06-19 Astrazeneca Ab New use II
SE0301795D0 (sv) * 2003-06-19 2003-06-19 Astrazeneca Ab New use I
EP2022110B1 (en) * 2006-05-11 2011-10-12 Johnson Controls Saft Advanced Power Solutions LLC Modular battery system
JP5163931B2 (ja) * 2007-03-08 2013-03-13 株式会社リコー 定着装置及び画像形成装置
EP2065385A1 (en) * 2007-11-28 2009-06-03 Laboratorios SALVAT, S.A. Stable crystalline salt of (R)-3-fluorophenyl-3,4,5-trifluorobenzylcarbamic acid 1-azabiciyclo [2.2.2]oct-3-yl ester
CN101747305B (zh) * 2008-11-28 2014-06-18 中国医学科学院药物研究所 硝克柳胺化合物晶v型、其制法和其药物组合物与用途
MX360896B (es) * 2013-04-26 2018-11-21 Sanofi Sa Sal tartrato de la [ (s)-2-[metil-3-(2-oxo-pirrolidin-1-il)-bencen osulfonilamino]-3-(4-metil-piperazin-1-il)-3-oxo-propil) amida de acido 5-cloro-tiofeno-2-carboxilico.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5616610A (en) 1989-12-22 1997-04-01 Astra Aktiebolag (R)-5-carbamoyl-8-fluoro-3-N,N-disubstituted-amino-3,4-dihydro-2H-1-benzopyrans
US5420151A (en) 1989-12-22 1995-05-30 Aktiebolaget Astra Chroman derivatives
IT1282705B1 (it) 1996-02-28 1998-03-31 Recordati Chem Pharm Uso di antagonisti del recettore serotoninergico 5-ht|a per il trattamento dell'incontinenza urinaria
US5990114A (en) 1996-02-28 1999-11-23 Recordati, S.A., Chemical And Pharmaceutical Company Use of 5-HT1A receptor antagonists for the treatment of urinary incontinence

Also Published As

Publication number Publication date
DE69809547T2 (de) 2003-08-21
US20050085532A1 (en) 2005-04-21
NZ501075A (en) 2001-08-31
RU2193560C2 (ru) 2002-11-27
EE03874B1 (et) 2002-10-15
IL133234A0 (en) 2001-03-19
BR9809519A (pt) 2000-06-20
IS1943B (is) 2004-08-13
SE9702066D0 (sv) 1997-05-30
SE9702066L (sv) 1998-12-01
WO1998054166A1 (en) 1998-12-03
US20030109576A1 (en) 2003-06-12
ATE228121T1 (de) 2002-12-15
HUP0001878A3 (en) 2002-04-29
JP2002501527A (ja) 2002-01-15
IL133234A (en) 2004-05-12
ZA984486B (en) 1998-11-30
NO995853L (no) 2000-01-31
US6858645B2 (en) 2005-02-22
DK0984952T3 (da) 2003-02-24
CN1258290A (zh) 2000-06-28
CN1198814C (zh) 2005-04-27
EP0984952A1 (en) 2000-03-15
SK282755B6 (sk) 2002-12-03
CA2291732C (en) 2003-12-30
AR012751A1 (es) 2000-11-08
PL337181A1 (en) 2000-08-14
AU7792398A (en) 1998-12-30
KR20010013127A (ko) 2001-02-26
EE9900549A (et) 2000-06-15
NO995853D0 (no) 1999-11-29
IS5270A (is) 1999-11-24
YU62499A (sh) 2002-06-19
SK159499A3 (en) 2000-10-09
BG103949A (en) 2000-07-31
ES2187030T3 (es) 2003-05-16
DE69809547D1 (de) 2003-01-02
JP3554338B2 (ja) 2004-08-18
TW510899B (en) 2002-11-21
HUP0001878A2 (hu) 2001-05-28
UA53720C2 (uk) 2003-02-17
AU729301B2 (en) 2001-02-01
SE510305C2 (sv) 1999-05-10
EP0984952B1 (en) 2002-11-20
HK1025575A1 (en) 2000-11-17
ID23794A (id) 2000-05-11
TR199902926T2 (xx) 2000-03-21
CA2291732A1 (en) 1998-12-03
MY117960A (en) 2004-08-30
PT984952E (pt) 2003-03-31

Similar Documents

Publication Publication Date Title
JP5086069B2 (ja) 重硫酸アタザナビルおよび新規形態の製造方法
JP5043825B2 (ja) Ｄｐｐ−ｉｖ阻害剤の新規な塩及び多形
JP2020183408A (ja) ｛［５−（３−クロロフェニル）−３−ヒドロキシピリジン−２−カルボニル］アミノ｝酢酸の固体形態、組成物、及びその使用
US6242460B1 (en) Zolpidem salt forms
CA3235361A1 (en) Polymorphs of the hydrochloride salt of linaprazan glurate
BG64051B1 (bg) Нова сол
JP5997162B2 (ja) アプレピタントｌ−プロリン組成物および共結晶
JP2012512145A (ja) フリバンセリンの結晶性の塩形態
US20090291953A1 (en) Pharmaceutical salts of reboxetine
RU2451016C2 (ru) Тозилатная соль транс-n-изобутил-3-фтор-3-[3-фтор-4-(пирролидин-1-илметил)фенил]циклобутанкарбоксамида
JP5959617B2 (ja) オタミキサバンの安息香酸塩
KR101557832B1 (ko) (ｒ)-3-플루오로페닐-3,4,5-트리플루오로벤질카르밤산 1-아자비시클로 [2.2.2]옥트-3-일 에스테르의 안정한 결정성 염
JP2018518515A (ja) フェニルアミノピリミジン化合物またはその塩の多形物
JP2914324B2 (ja) ピペリジン誘導体の結晶並びにその製造中間体及び製造方法
MXPA99010942A (en) A new salt
TW202216726A (zh) 八氫噻吩并喹啉化合物之琥珀酸鹽及其結晶
CN112851643B (zh) 嘧啶苯甲酰胺化合物的盐酸盐及其用途
CZ426199A3 (cs) Nová sůl
EP3517529B1 (en) Salt of quinazoline derivative, preparation method therefor and application thereof
CN105218528A (zh) 一种l-酒石酸坦度螺酮化合物
CN112851641A (zh) 嘧啶苯甲酰胺化合物的盐酸盐及其用途